Selective MC1R-preferring agonist; stimulates eumelanin synthesis in melanocytes, providing photoprotection.
Reference facts
- Also known as
- Melanotan I, Scenesse, [Nle⁴, D-Phe⁷]-α-MSH
- Category
- Sexual Health & MSH
- Mechanism of action
- Selective MC1R-preferring agonist; stimulates eumelanin synthesis in melanocytes, providing photoprotection.
- Targets
- MC1R
- Indications under research or approved
- Erythropoietic Protoporphyria (EPP), Adult variegate porphyria (orphan)
- Regulatory status (reference entry)
- FDA-approved (2019, Scenesse implant)
- Half-life
- ~30 minutes (formulated as long-acting subcutaneous implant)
- Sequence notes
- Linear analog Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2; 13 residues.
- Molecular weight (Da)
- 1647
- Originator / sponsor
- Clinuvel Pharmaceuticals
- First reported
- 1980
Primary References
Explore research articles about Afamelanotide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.